The broader life sciences sector saw a spate of deal activity in recent weeks, with two acquisitions over the billion-dollar mark and several more in the h
Increased regulatory intervention is here to stay, and deal teams must remain agile and skilful to meet the evolving challenges as Douglas Abernethy, Nick Cline, Robbie McLaren and Catherine Campbell explain